Immunovant (IMVT) said Wednesday its proof-of-concept study for batoclimab showed potential for treating patients with uncontrolled Graves' disease, an autoimmune disorder.

Six-month off-treatment data in uncontrolled Graves' disease patients treated with batoclimab for 24 weeks showed that around 80% of the patients demonstrated response, resulting in normal thyroid function, the company said.

Of the responders to the therapy, around 50% achieved anti-thyroid drug free remission six months after the end of the treatment, Immunovant said.

The company said it is currently enrolling for two potentially registrational trials for its lead compound IMVT-1402 in Graves' disease, with topline readouts expected in 2027.

Shares of Immunovant were up 10% in recent trading Wednesday.

Price: 15.75, Change: +0.67, Percent Change: +4.48